Results from the present study suggest that a combination of S1PR1 antagonist with VEGF-VEGFR2 inhibitors could represent the first step toward treating VEGFR2 refractory tumors and prove relevant in other cancers driven by VEGF-VEGFR2 signaling. This evidence concerns the gene S1PR1 and cancer.